Adjuvant chemoimmunotherapy for gastric carcinoma

Area of Science:

• Oncology
• Immunotherapy
• Gastrointestinal Cancer Research

Background:

• Gastric carcinoma remains a significant global health challenge.
• Adjuvant therapies are crucial for improving outcomes after palliative resection.
• The role of immunotherapy in gastric cancer treatment requires further investigation.

Purpose of the Study:

• To evaluate the efficacy of bacille Calmette Guérin (BCG) immunotherapy combined with 5-fluorouracil in treating gastric carcinoma.
• To assess the impact of 5-fluorouracil as an adjuvant therapy on survival rates in patients with gastric carcinoma.

Main Methods:

• A randomized study involving 78 gastric carcinoma patients between July 1974 and August 1978.
• Two treatment arms: BCG and 5-fluorouracil versus 5-fluorouracil alone.
• Comparison of survival rates with a control group receiving no additional treatment post-palliative resection.

Main Results:

• Bacille Calmette Guérin (BCG) immunotherapy did not demonstrate a significant effect on patient survival.
• Adjuvant 5-fluorouracil therapy following palliative resection led to improved survival compared to no additional treatment.
• Initial findings suggest a potential benefit of aggressive management for incurable gastric carcinoma.

Conclusions:

• Current immunotherapy protocols (BCG) did not enhance survival in this gastric carcinoma cohort.
• 5-fluorouracil as an adjuvant therapy shows promise for improving survival in advanced gastric cancer.
• Further multicentre randomized prospective trials are warranted to confirm these findings and guide aggressive management strategies.